Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Differentiation of multiple sclerosis subtypes: implications for treatment.

Andreas Bitsch1, Wolfgang Brück

  • 1Department of Neurology, Ruppiner Kliniken GmbH, Neuruppin, Germany. wolfgang.brueck@charite.de

CNS Drugs
|May 25, 2002
PubMed
Summary

Multiple sclerosis (MS) treatment varies due to disease heterogeneity. Identifying specific MS subtypes through biomarkers could enable targeted immunomodulatory therapies for better patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantitative T1 is sensitive to cortical remyelination in multiple sclerosis: A postmortem MRI study.

Brain pathology (Zurich, Switzerland)·2025
Same author

Impaired remyelination in late-onset multiple sclerosis.

Acta neuropathologica·2025
Same author

Characteristics, Prevalence, and Clinical Relevance of Juxtacortical Paramagnetic Rims in Patients With Multiple Sclerosis.

Neurology·2024
Same author

Serum neurofilament light chains in progressive multiple sclerosis patients treated with repeated cycles of high-dose intravenous steroids.

Free neuropathology·2023
Same author

Development and multi-center validation of a fully automated digital immunoassay for neurofilament light chain: toward a clinical blood test for neuronal injury.

Clinical chemistry and laboratory medicine·2023
Same author

Long-term clinical, imaging and cognitive outcomes association with MS immunopathology.

Annals of clinical and translational neurology·2023

Area of Science:

  • Neuroimmunology
  • Clinical Neurology
  • Pathology

Background:

  • Recent advancements in immunomodulatory treatments for multiple sclerosis (MS) include interferon-beta, glatiramer acetate, and mitoxantrone.
  • Despite effective treatments for some, not all MS patients respond well, suggesting significant disease heterogeneity.
  • Clinical presentation alone does not fully capture MS heterogeneity, necessitating deeper pathological understanding.

Purpose of the Study:

  • To explore the link between multiple sclerosis (MS) disease heterogeneity and patient response to immunomodulatory therapies.
  • To highlight the need for in vivo markers to identify specific MS immunopathogenesis subtypes for personalized treatment.
  • To discuss potential targeted therapies for distinct MS pathological subtypes.

Main Methods:

Related Experiment Videos

  • Analysis of biopsy and autopsy specimens to identify distinct oligodendrocyte/myelin pathology and immunopathology subtypes in MS.
  • Review of clinical data correlating disease course (relapsing-remitting vs. progressive) with treatment response.
  • Theoretical evaluation of therapeutic strategies for identified MS subtypes.

Main Results:

  • At least four distinct MS subtypes identified based on histopathology, indicating limitations of clinical classification.
  • Relapsing-remitting MS patients show better response to immunomodulatory therapy than those with progressive MS.
  • Inconsistent results in secondary progressive MS and no positive trials in primary progressive MS suggest subtype-specific responses.

Conclusions:

  • Histopathological subtyping is crucial for understanding MS heterogeneity, but in vivo markers are needed for differential therapy.
  • Potential targeted therapies include plasmapheresis/IVIg for antibody-mediated subtypes and interferon-beta/glatiramer acetate for inflammatory subtypes.
  • Future therapies may address viral or oligodendrocyte degeneration-related MS subtypes with antiviral or regenerative approaches.